Â鶹´«Ã½

Skip to main content

Weight-loss market to see 16 new drugs by 2029, report estimates

FILE - The injectable drug Ozempic is shown Saturday, July 1, 2023, in Houston. (David J. Phillip / AP Photo, File) FILE - The injectable drug Ozempic is shown Saturday, July 1, 2023, in Houston. (David J. Phillip / AP Photo, File)
Share

The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk and Eli Lilly, according to estimates from analysts at Morningstar and Pitchbook.

In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to US$200 billion by 2031. The 16 drugs could launch by 2029, with roughly US$70 billion of the GLP-1 market coming from these new challengers.

Why it's important

Surging demand for Novo's Wegovy and Lilly's Zepbound has sparked interest among competitors to test their own weight-loss treatments. Companies such as Amgen and Pfizer are currently testing their drug candidates in clinical trials.

These developments come amid criticism from lawmakers over the high costs associated with these medications. The new entrants, however, are expected to drive down prices as they vie for market share, according to the report.

Context

The potential new treatments include those from Boehringer Ingelheim and Zealand Pharma, along with competitors from Roche, Amgen and Pfizer, according to the report, provided that the drugs clear clinical trials.

Other entrants include those by Structure Therapeutics, Viking Therapeutics and Altimmune, along with next-generation drugs by Novo and Lilly.

Analysts, last year, had forecast the obesity market would be US$170 billion by 2031, but have recently raised their estimates, partly due to anticipated higher diabetes market penetration.

The report projects 41 per cent individuals with diabetes and nearly one-quarter of nondiabetic obesity patients will be on a GLP-1 drug by 2031.

What's next?

Analysts expect significant acquisitions by major pharmaceutical companies in the obesity sector over the next 18 months, targeting smaller companies specializing in obesity drug development.

Potential acquisition targets include firms such as Structure, Viking and Altimmune.

Private companies such as NodThera, Corteria and Diasome have a higher-than-50 per cent chance of being acquired, according to PitchBook data.

(Reporting by Sneha S K in Bengaluru; Editing by Mohammed Safi Shamsi)

CTVNews.ca Top Stories

A driver suffered only minor injuries after going airborne in a residential neighbourhood in Maple Ridge, B.C., on Friday, the car eventually landing on its roof in someone’s backyard.

The owners of a North York condominium say they are facing a $70,000 special assessment to fix their building's parking garage. '$70,000 is a lot of money. It makes me very nervous and stressed out of nowhere for this huge debt to come in,' said Ligeng Guo.

Police released the identities of the mother and daughter who were killed after a fire tore through a 160-year-old building in Old Montreal on Friday.

The sentencing of the man who pleaded guilty in the deadly hit-and-run in Kitsilano two years ago began on Friday.

Local Spotlight

Chantal Kreviazuk is set to return to Winnipeg to mark a major milestone in her illustrious musical career.

From the beaches of Cannes to the bustling streets of New York City, a new film by a trio of Manitoba directors has toured the international film festival circuit to much pomp and circumstance.

A husband and wife have been on the road trip of a lifetime and have decided to stop in Saskatchewan for the winter.

The grave of a previously unknown Canadian soldier has been identified as a man from Hayfield, Man. who fought in the First World War.

A group of classic car enthusiasts donated hundreds of blankets to nursing homes in Nova Scotia.

Moving into the second week of October, the eastern half of Canada can expect some brisker fall air to break down from the north

What does New Westminster's təməsew̓txʷ Aquatic and Community Centre have in common with a historic 68,000-seat stadium in Beijing, an NFL stadium and the aquatics venue for the Paris Olympics? They've all been named among the world's most beautiful sports venues for 2024.

The last living member of the legendary Vancouver Asahi baseball team, Kaye Kaminishi, died on Saturday, Sept. 28, surrounded by family. He was 102 years old.

New data from Greater Vancouver and the Fraser Valley shows a surge in supply and drop in demand in the region's historically hot real estate market.